P30563.P04			Sheet 1 of 2
FORM PTO-1449	U.S. Department of Commerce	Atty. Docket No.	Application No.

		Patent and Trademark Office P3065								P30653	30653				10/598,275			
										Applicant Ryozo NAGAI et al.								
•	(Use several sheets if necessary)										Filing Date February 24, 2005				Group 1611 Unknown			
		_							U.S. PATEN	T DOCUMI	NTS	_						
EXAMINER														T		FILING DATE		
INITIAL		4	DOCUMENT NUMBER DATE NAME 4 9 1 7 8 2 9 04/17/90 YAMATSU et al.					+	CLASS		BCLASS	IF APPROPRIATE						
		4	9	1	7	8	2	9	04/17/90	YAMAI	SU et al.	-+		+				
	l	_							FOREIGN PAT	FATE DOCL	MENTE							
		_							FOREIGN PAT	ENI DOCC	MENIS				т	TD ANG	LATION	
			DO	CUM	ENT	NUM	BER		DATE	cou	CLASS SUB		CLASS YES		NO NO			
	56	-	1	4	0	9	4	9	11/04/81	JAPAN								
	63	-		3	2	0	5	8	06/28/82	JAPAN								
	7	•	1	1	2	9	3	0	05/02/95	JAPAN								
	61	-	2	1	0	0	5	0	09/18/86	JAPAN								
-		0	1	9	4	6	9	3	09/19/86	E.P.O								
	59	-	1	0	1	4	4	8	06/12/84	JAPAN								
		0	1	1	0	3	9	7	06/13/84	E.P.O								
	10	-	3	1	6	6	1	7	12/02/98	JAPAN								
	4	-	1	7	8	3	4	8	06/25/92	JAPAN								
	11	-	3	1	8	4	5	0	11/24/99	JAPAN								
	2003	/	0	8	9	0	0	5	10/30/05	W.I.P.O								
	2005	/	0	1	0	1	8	5	02/03/05	W.I.P.O	ĺ							
					отн	ER D	ocu	MEN	TS (Including A	Author, Title	, Date, Pertine	ent P	ages, Etc.)	,				
	1								ion of Intima iol. Feb. 2004					by a	Nontoxic	Ras Inhi	bitor",	
	2								on of Second Carcinoma", l									
	3	SM		b/No					TEB2, A Kı Heavy Chain									
	4	T. SHINDO et al., "Kruppel-Like Zinc-Finger Transcription Factor KLF5/BTEB2 is a Target for Angiotensin II Signaling and an Essential Regulator of Cardiovascular Remodeling", Nature Medicine, Vol. 8, No. 8, pp.856-863, July 8, 2002.											No. 8,					
	5	J. DAVIS et al., "Cartenoids and Related Compounds. Part XV. The Structure and Synthesis of Phytoene, Phytofluene, ζ-Carotene, and Neurosporene", J. Chem. Soc., 1966, pp.2154-2165.																
EXAMINER		_		_						DAT	E CONSIDER	ED						
*EXAMINER: I									is in conforman	ce with MPE	P 609; draw lin	e thr	ough citati	ion if no	t in conforma	ance and not	considered.	

P30563.P04		-							Sh	eet 2 of 2	
FORM PTO-	1449		epartment of Co	Atty. Doc P30653	ket No.	_	Application No. 10/598,275				
ξ.	INFORM	IATION DISCLOSURE STA	TEMENT	Applicant Ryozo NAGAI et al.							
•	(Use several sheets if necessar	у)		Filing Dar February			Group Unknown			
			U.S. PATENT	r DOCUM!	ENTS			-			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	su	BCLASS	FILING DATE IF APPROPRIATE		
02/10/20	8		-				-				
	1		FOREIGN PATI	ENT DOCI	IMENTS						
	T			Ent. Book					TRANS	LATION	
		DOCUMENT NUMBER	DATE	cou	NTRY	CLASS	SUB	CLASS	YES	NO	
	1										
				-							
		OTHER DOCUM	ENTS (Including A	uthor, Title	e, Date, Pertin	ent Pages, Etc.)				
	6	English language Abstract	of JP 56-140949) .				•			
	7	English language Abstract of JP 7-112930.									
	8	English language Abstract of JP 61-210050.									
	9	English language Abstract of JP 10-316617.									
	10	English language Abstract									
	11	English language Abstract									
	12	U.S. Patent Application 10 Vascular Disease"			.), entitled,	"Medicame	nt for	Therapeu	tic Treatm	ent of	
	13	U.S. Patent Application 10	/565,997 (NAC	AI et al.), entitled, '	'RNA Capal	le of S	Suppressir	g Express	sion of	

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Patent Application 11/366,454 (NAGAI et al.), entitled, "Medicament Having Neovascularization

DATE CONSIDERED

02/10/2008

14

EXAMINER

Promoting Action".